 PHILADELPHIA, PA, Feb. 12, 2021 GLOBE NEWSWIRE -- Vallon Pharmaceuticals Inc. NASDAQ: VLON Vallon or the Company, a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the closing of its initial public offering of 2,250,000 shares of common stock at a public price offering of 8.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Vallon, were 18.0 million. In addition, Vallon has granted the underwriters a 45-day option to purchase up to an additional 337,500 shares of Vallons common stock at the initial public offering price, less underwriting discounts and commissions. 